Результаты поиска

Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan.

Multiple myeloma is a cancer of plasma cells; the incidence rate of multiple myeloma is high among older adults. Although significant advances have been made in the clinical management of multiple myeloma driven by the introduction of novel drugs, such as proteasome inhibitors, immuno- modulators and antibodies, multiple myeloma remains incurable. Hence, the current therapeutic goal for multiple myeloma is to achieve long-term survival while maintaining a good quality of life. In this context, personalized treatment to balance the efficacy and safety of therapies is important, especially for o

Antibiotic lock therapy for the treatment of peripherally inserted central venous catheter-related bloodstream infection in patients with hematological malignancies: a single center retrospective study.

Catheter-related bloodstream infections represent one of the most prevalent complications in patients with peripherally inserted central venous catheters (PICCs). The application of antibiotic lock therapy (ALT), particularly in patients with hematological malignancies, has not been well documented. We aim to share our experience on ALT for these patients and to evaluate its effectiveness and safety. All cases of patients with hematological malignancies who had PICC from January 2018 to October 2024 were retrospectively reviewed. Microbiologic data of PICC-related bloodstream infections (PRBSI

Лечение для пожилых пациентов из числа миеломы.

Замечательные успехи были достигнуты в лечении нескольких пациентов, страдающих миеломой (ММ); однако для слабых пожилых пациентов эти результаты лечения по-прежнему недостаточны. Увеличивается число пожилых пациентов с МР, равно как и число пациентов, проходящих курс лечения. Существует повышенный спрос на оценку этих пациентов в целях обеспечения оптимальных методов лечения. Несмотря на то, что непрерывное лечение чаще случается у пациентов с ОМ по сравнению с стационарным лечением, из-за риска прерывания лечения, что приводит к снижению показателей выживаемости, важное значение имеют эффект

MSC Senescence-Related Genes Are Associated with Myeloma Prognosis and Lipid Metabolism-Mediated Resistance to Proteasome Inhibitors.

BackgroundComplex carcinogenic mechanisms and the existence of tumour heterogeneity in multiple myeloma (MM) prevent the most commonly used staging system from effectively interpreting the prognosis of patients. Since the microenvironment plays an important role in driving tumour development and MM occurs most often in middle-aged and elderly patients, we hypothesize that ageing of bone marrow mesenchymal stem cells (BM-MSCs) may be associated with the progression of MM.MethodsIn this study, we collected the transcriptome data on MM from The Cancer Genome Atlas (TCGA) and the Gene Expression O

Multiple myeloma: an overview of management.

Multiple myeloma represents 2% of all new cancer diagnoses in the United Kingdom and accounts for 2% of all cancer deaths. In the past few decades, there have been huge improvements in life expectancy which have been driven by novel therapeutic agents, autologous stem cell transplants and intensified supportive care. This review will discuss the pathogenesis of multiple myeloma, current management approaches and the direction of future treatments. In addition, this review will highlight the high burden of symptoms that patients experience and therefore the great benefits that can be gained fro

Assessment of the Diagnostic Potential of miR-29a-3p and miR-92a-3p as Circulatory Biomarkers in Acute Myeloid Leukemia.

BACKGROUND: Acute myeloid leukemia (AML) is a set of Myeloproliferative neoplasms that are identified by excessive growth of myeloid blasts and production of abnormal blood cells. AML is the most common type of acute leukemia that occurs in adults. In addition, AML progresses rapidly and is considered a fatal disease. Thus, there is an urgent need to find new targets for molecularly designed therapies. In This study, we evaluated the circulatory levels of microRNA-29a-3p (miR-29a-3p) and miR-92a-3p beside exploring the expression pattern of their target gene myeloid cell leukemia sequence1 (MC

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.

Maintenance therapy after autologous stem cell transplantation (ASCT) is recommended for use in multiple myeloma (MM); however, more data are needed on its impact on health-related quality of life (HRQoL). Presented here is an analysis of HRQoL in a Connect MM registry cohort of patients who received ASCT ± maintenance therapy. The Connect MM Registry is one of the earliest and largest, active, observational, prospective US registry of patients with symptomatic newly diagnosed MM. Patients completed the Functional Assessment of Cancer Therapy-MM (FACT-MM) version 4, EuroQol-5D (EQ-5D) question

Разграничение Genotype X Environment Cooperation for Green Yeeld в Весне Барли в условиях необработанной и фунгицидной среды.

Барли (Hordeul vulgare L.) — четвёртый по величине урожай зерновых культур, выращиваемый на основе производства и возделывания. Биотические стрессы, особенно грибковые заболевания в ячменях, являются разрушительными и сопряжены с высокой вероятностью абсолютной потери урожайности. Для удовлетворения растущего спроса на ячмень решающее значение имеет выявление более высоких и стабильных генотипов. Вместе с тем выявление и рекомендация генотипов высшего сорта сопряжены с трудностями из-за взаимосвязи между генотипом и окружающей средой. Таким образом, настоящее исследование было направлено на оц

Прогнозирующие детерминанты долгосрочной смертности у пожилых пациентов с новой диагностированной множественной миеломой.

Фон/цели: Множественная миелома (ММ) — опухоль плазменной клетки, диагностированная преимущественно у пожилых людей. Вместе с тем еще предстоит твердо установить значение определения слабой стороны пациента, а также определения наиболее подходящих и надежных инструментов для его оценки. Методы: Это ретроспективное исследование 36 больные в возрасте 65 - лица более старшего возраста, прошедшие комплексную гериатрическую оценку (CGA). Средний возраст пациентов 76 (СД) 6.22) с 33.3% быть женщиной. Оценка пациентов проводилась с использованием индекса упругости Международной рабочей группы по миел

Exploring the evolving role of apolipoproteins in oncology: global trends and emerging frontiers.

BackgroundMetabolic reprogramming, especially lipid metabolism, is crucial in cancer progression and treatment resistance. Apolipoproteins are crucial targets for research as they regulate autophagy, oxidative stress, and chemoresistance. A systematic bibliometric and bioinformatics approach is necessary to identify trends and elucidate the molecular mechanisms linking apolipoproteins to cancer.MethodsA systematic bibliometric analysis was conducted using the Web of Science Core Collection and PubMed. VOSviewer, CiteSpace, and the Bibliometrix R package were employed to analyze and visualize c

Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs.

Although the significant strides in novel therapeutic approaches have prolonged the survival of multiple myeloma (MM) patients, the unfavorable prognosis of cytogenetically high-risk newly diagnosed MM (NDMM) remains intractable with the lack of consensus regarding the choice of maintenance regimens. Therefore, this study was initiated with the aim of examining the effectiveness of various maintenance treatments for this group of patients in jeopardy. Overall, 17 studies with 1937 high-risk NDMM patients were included in the network meta-analysis. Combination therapies involving novel drugs pr

Research Advances on Targets and Mechanisms in Cancers Complicated by Cardiovascular Diseases.

PurposeCancers complicated by cardiovascular diseases (CVDs) are increasingly becoming major limiting factors affecting patients' long-term quality of life and clinical outcomes. Systematic identification of therapeutic targets and their clinical development status is crucial for optimizing treatment strategies. Therefore, this study aimed to establish a target-based analytical framework to systematically map the distribution, developmental stage, maturity, and mechanistic characteristics of clinical trials investigating tumors co-occurring with CVD, thereby identifying potential therapeutic t

Совпадение в полном тексте источника
… Effect of factor XI inhibition on tumor cell-induced coagulation activation. J Thromb Haemost . 2024;22(1):199–212. doi: 10.1016/j.jtha.2023.09.015 20. Kobayashi M, Wada H, Fukui S, et al. A clot waveform analysis showing a hypercoagulable state in patients with malignant neoplasms. … Factor XI inhibitors and atrial fibrillation: imminent breakthrough or false start? Eur Heart J Suppl . 2025;27(Suppl 3):iii46–iii53. doi: 10.1093/eurheartjsupp/suaf015 70. Pacher P, Liaudet L, Bai P, et al. …

Сердечно-сосудистые заболевания

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Окончательные анализы OS на ТУРМАЛИНЕ-ММ3 и -ММ4 РТС ixazomib технического обслуживания в недавно диагностированном множестве миелом.

TOURMALINE-MM3 (В тыс.NCT02181413) и -ММ4 (NCT02312258) были фазы 3 :: исследования по обслуживанию ixazomib в течение длительного периода времени в период после трансплантации (TOURMALINE-MM3)/приемлемый для трансплантации (TOURMALINE-MM4) пациенты с недавно поставленным диагнозом множественной миеломы (NDMM), которые продемонстрировали улучшение среднего уровня выживаемости без прогрессирования (PFS) для ixazomib vs placebo. Мы представляем анализы окончательного общего выживания (ОС) по каждому исследованию отдельно. В обоих исследованиях пациенты, имеющие право на получение пособия, были с

Clinical Characteristics, Cytogenetic Risks, and Prognoses of Young Multiple Myeloma Patients in the Era of Novel Therapies.

Background/Objectives: In recent years, there have been significant advances in the understanding and treatment of multiple myeloma (MM). Despite this progress, there is still limited information on the disease in patients aged 50 or younger, including the impact of young age on disease characteristics, treatment, and outcome. Methods: In this retrospective study, we analyzed 68 newly diagnosed MM patients aged ≤ 50 years (y) who had undergone at least one peripheral blood stem cell transplantation (PBSCT). Additionally, we reviewed data published during 2008-2022 and compared these to our coh

Lenalidomide and Dexamethasone in Scleromyxedema: A Case Report of Long-Term Efficacy and Challenges in a 54-Year-Old Patient.

Lichen myxedematosus (LM) is characterized by dermal mucin buildup, fibroblast proliferation, and variable presentation. The diffuse variant, known as scleromyxedema, is identified by monoclonal paraprotein presence and lack of thyroid issues, with considerations for infections and underlying conditions. Despite lacking FDA-approved treatment, intravenous immunoglobulin stands as effective, although resource-intensive, while targeting the clonal source of pathogenic immunoglobulin offers an alternate therapeutic route. Our case explores the efficacy of an oral plasma cell-focused lenalidomide

Rapidly Progressive Acute Liver Failure in Relapsed Multiple Myeloma.

Multiple myeloma affects upwards of 30,000 people every year and has significant morbidity and mortality. Common complications of the disease involve lytic bone lesions, hypercalcemia, anemia, and acute renal failure. A rare, yet serious, complication includes acute liver failure secondary to hepatic plasma cell infiltration. While this is reported seldom in living patients, it is found in upwards of 40% of patients incidentally on imaging or during autopsy. Conscientious and meticulous monitoring of liver function tests allows for early detection of liver failure in multiple myeloma; thus, al

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.

The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study (NCT02181413) demonstrated improved progression-free survival with ixazomib maintenance versus placebo post autologous stem cell transplant (ASCT) in multiple myeloma patients. We report additional safety data from TOURMALINE-MM3 to inform adverse event (AE) management recommendations. Patients were randomized 3:2 to receive ixazomib (n = 395) or placebo (n = 261) on days 1, 8, and 15 of 28-day cycles for ~ 2 years or until progressive disease/toxicity. The initial 3-mg ixazomib dose was escalated to 4 mg in cycle 5, if tolerat

Reliable information for cancer control in Cali, Colombia.

BackgroundThe Cali Population Cancer Registry (RPCC) has been in continuous operation since 1962 with the objective of producing valid statistics on the incidence of cancer, its patterns, trends and survival rates.MethodsDuring the period 2008-2012, 23,046 new cases were registered and during 2011-2015 there were 12,761 cancer deaths. The trend of the rates was described with the APC average annual change rate and with the Joinpoint analysis. We analyzed the individual data of 38,671 adults (15-99 years) diagnosed with cancer between 1995-2009, and we calculated the standardized net survival b

Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies.

Multiple myeloma (MM) is still considered an incurable hematologic cancer and, in the last decades, the treatment goal has been to obtain a long-lasting disease control. However, the recent availability of new effective drugs has led to unprecedented high-quality responses and prolonged progression-free survival and overall survival. The improvement of response rates has prompted the development of new, very sensitive methods to measure residual disease, even when monoclonal components become undetectable in patients' serum and urine. Several scientific efforts have been made to develop reliab